Laurie K Bale Selected Research

Pregnancy-Associated Plasma Protein-A (PAPP-A)

1/2022	Pregnancy-associated plasma protein-A (PAPP-A) is a key component of an interactive cellular mechanism promoting pulmonary fibrosis.
10/2020	Genetic and Pharmacological Inhibition of PAPP-A Protects Against Visceral Obesity in Mice.
1/2020	Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.
10/2016	PAPP-A in normal human mesangial cells: effect of inflammation and factors related to diabetic nephropathy.
2/2016	Targeted Inhibition of Pregnancy-Associated Plasma Protein-A Activity Reduces Atherosclerotic Plaque Burden in Mice.
1/2016	Comparative gene expression and phenotype analyses of skeletal muscle from aged wild-type and PAPP-A-deficient mice.
10/2015	Pregnancy-associated plasma protein-A deficiency improves survival of mice on a high fat diet.
4/2015	A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts.
4/2014	Inducible reduction in pregnancy-associated plasma protein-A gene expression inhibits established atherosclerotic plaque progression in mice.
8/2013	Inducible knock out of pregnancy-associated plasma protein-a gene expression in the adult mouse: effect on vascular injury response.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laurie K Bale Research Topics

Disease

5	Atherosclerotic Plaque (Atheroma) 02/2016 - 01/2006
5	Atherosclerosis 02/2016 - 10/2003
4	Neoplasms (Cancer) 04/2015 - 09/2002
3	Ovarian Neoplasms (Ovarian Cancer) 04/2015 - 09/2002
3	Vascular System Injuries 08/2013 - 01/2006
2	Inflammation (Inflammations) 10/2016 - 10/2015
2	Cardiovascular Diseases (Cardiovascular Disease) 02/2016 - 04/2014
2	Hyperplasia 01/2013 - 01/2006
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Fatty Liver 10/2020
1	Abdominal Obesity 10/2020
1	Polycystic Kidney Diseases (Polycystic Kidney Disease) 01/2020
1	Cysts 01/2020
1	Autosomal Dominant Polycystic Kidney (ADPKD) 01/2020
1	Diabetic Nephropathies (Diabetic Nephropathy) 10/2016
1	Hyperglycemia 10/2016
1	Hypercholesterolemia 02/2016
1	Fatigue 01/2016
1	Cardiomyopathies (Cardiomyopathy) 01/2016
1	Weight Gain 10/2015
1	Ascites 04/2015
1	Neointima 01/2013
1	Death (Near-Death Experience) 06/2010
1	Atrophy 07/2009
1	Carcinoma (Carcinomatosis) 09/2002
1	Ovarian Epithelial Carcinoma 09/2002

Drug/Important Bio-Agent (IBA)

19	Pregnancy-Associated Plasma Protein-A (PAPP-A)IBA 01/2022 - 07/2004
5	Insulin-Like Growth Factor I (IGF-1)IBA 01/2022 - 10/2003
5	Metalloproteases (Metalloproteinases)IBA 01/2020 - 02/2007
4	Insulin-Like PeptidesIBA 10/2016 - 02/2007
3	Messenger RNA (mRNA)IBA 01/2022 - 07/2004
2	Monoclonal AntibodiesIBA 01/2020 - 02/2016
2	Insulin-Like Growth Factor Binding ProteinsIBA 01/2020 - 01/2013
2	Triglycerides (Triacylglycerol)IBA 02/2016 - 04/2014
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022
1	Advanced Glycation End ProductsIBA 10/2016
1	Interleukin-6 (Interleukin 6)IBA 10/2016
1	PlatinumIBA 04/2015
1	Neutralizing AntibodiesIBA 04/2015
1	Proteins (Proteins, Gene)FDA Link 04/2015
1	ZincIBA 04/2014
1	CholesterolIBA 04/2014
1	Insulin-Like Growth Factor Binding Protein 4IBA 01/2013
1	ApolipoproteinsIBA 08/2010
1	Apolipoproteins E (ApoE)IBA 08/2010
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2006
1	CytokinesIBA 01/2006
1	Insulin-Like Growth Factor II (Somatomedin A)IBA 09/2002
1	Insulin (Novolin)FDA Link 09/2002
1	Protein Isoforms (Isoforms)IBA 09/2002
1	Insulin ReceptorIBA 09/2002

Therapy/Procedure

1	Therapeutics 04/2015
1	Drug Therapy (Chemotherapy) 04/2015
1	Ligation 01/2013